These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 16495387)

  • 1. Response to expression of concern regarding VIGOR study.
    Bombardier C; Laine L; Burgos-Vargas R; Davis B; Day R; Ferraz MB; Hawkey CJ; Hochberg MC; Kvien TK; Schnitzer TJ; Weaver A
    N Engl J Med; 2006 Mar; 354(11):1196-9. PubMed ID: 16495387
    [No Abstract]   [Full Text] [Related]  

  • 2. Response to expression of concern regarding VIGOR study.
    Reicin A; Shapiro D
    N Engl J Med; 2006 Mar; 354(11):1196-9. PubMed ID: 16544387
    [No Abstract]   [Full Text] [Related]  

  • 3. Expression of concern reaffirmed.
    Curfman GD; Morrissey S; Drazen JM
    N Engl J Med; 2006 Mar; 354(11):1193. PubMed ID: 16495386
    [No Abstract]   [Full Text] [Related]  

  • 4. Effects of rofecoxib and naproxen on life expectancy among patients with rheumatoid arthritis: a decision analysis.
    Choi HK; Seeger JD; Kuntz KM
    Am J Med; 2004 May; 116(9):621-9. PubMed ID: 15093759
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The lessons of Vioxx--drug safety and sales.
    Waxman HA
    N Engl J Med; 2005 Jun; 352(25):2576-8. PubMed ID: 15972862
    [No Abstract]   [Full Text] [Related]  

  • 6. [Overestimated].
    Höer A; Häussler B
    Med Klin (Munich); 2006 Aug; 101(8):676-7; author reply 678-9. PubMed ID: 17051671
    [No Abstract]   [Full Text] [Related]  

  • 7. The Vioxx fallout.
    Palmer K
    Minn Med; 2005 Mar; 88(3):26-30. PubMed ID: 15852592
    [No Abstract]   [Full Text] [Related]  

  • 8. Is rofecoxib safer than naproxen?
    Adelman A
    J Fam Pract; 2001 Mar; 50(3):204. PubMed ID: 11252204
    [No Abstract]   [Full Text] [Related]  

  • 9. The lessons of Vioxx.
    Frazier KC
    N Engl J Med; 2005 Sep; 353(13):1420-1; author reply 1420-1. PubMed ID: 16192497
    [No Abstract]   [Full Text] [Related]  

  • 10. Life after Vioxx: the clinical implications.
    Fortun PJ; Hawkey CJ
    Hosp Med; 2005 May; 66(5):264-7. PubMed ID: 15920854
    [No Abstract]   [Full Text] [Related]  

  • 11. The withdrawal of rofecoxib.
    Arellano FM
    Pharmacoepidemiol Drug Saf; 2005 Mar; 14(3):213-7. PubMed ID: 15724267
    [No Abstract]   [Full Text] [Related]  

  • 12. The trade-off between cardiovascular and gastrointestinal effects of rofecoxib.
    Florentinus SR; Heerdink ER; de Boer A; van Dijk L; Leufkens HG
    Pharmacoepidemiol Drug Saf; 2005 Jul; 14(7):437-41. PubMed ID: 15937867
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The selective Cox-2 inhibition by rofecoxib reduces risk of severe gastrointestinal complications of anti-inflammatory therapy by more than 50%].
    Kellner H
    Z Gastroenterol; 2001 May; 39(5):443-5. PubMed ID: 11413920
    [No Abstract]   [Full Text] [Related]  

  • 14. Unnecessary withdrawal of Vioxx.
    Adams D
    N Z Med J; 2004 Oct; 117(1204):U1130. PubMed ID: 15505673
    [No Abstract]   [Full Text] [Related]  

  • 15. [Coxib instead of NSAID plus gastric acid inhibitor. Protection for the small intestine].
    MMW Fortschr Med; 2004 Mar; 146(13):61. PubMed ID: 15219139
    [No Abstract]   [Full Text] [Related]  

  • 16. A quantitative evaluation of the regulatory assessment of the benefits and risks of rofecoxib relative to naproxen: an application of the incremental net-benefit framework.
    Lynd LD; Marra CA; Najafzadeh M; Sadatsafavi M
    Pharmacoepidemiol Drug Saf; 2010 Nov; 19(11):1172-80. PubMed ID: 20602338
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lapses at the new England journal of medicine.
    Smith R
    J R Soc Med; 2006 Aug; 99(8):380-2. PubMed ID: 16893926
    [No Abstract]   [Full Text] [Related]  

  • 18. Report of specific cardiovascular outcomes of the ADVANTAGE trial.
    Braunstein N; Polis A
    Ann Intern Med; 2005 Jul; 143(2):158-9. PubMed ID: 15968005
    [No Abstract]   [Full Text] [Related]  

  • 19. Discontinuation of Vioxx.
    Lièvre M; Abadie E;
    Lancet; 2005 Jan 1-7; 365(9453):23-4; author reply 26-7. PubMed ID: 15639668
    [No Abstract]   [Full Text] [Related]  

  • 20. [How many harmed by rofecoxib in Germany?].
    Scharnetzky E; Andersohn F; Schill W; Garbe E; Pigeot I
    Med Klin (Munich); 2006 Aug; 101(8):675-6; author reply 678-9. PubMed ID: 17051670
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.